Form 10-Q SYNERGY PHARMACEUTICALS, For: Mar 31

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/9/2026

1. SPCX
2. HUM
3. ALHC
4. T
5. PEP
6. CVS
7. UNH
8. SBUX
9. AXP
10. ZETA

Go back to Form 10-Q SYNERGY PHARMACEUTICALS, For: Mar 31

Synergy Pharma (SGYP) Misses Q1 EPS Views; Offers Corp. Update

May 10, 2016 4:36 PM EDT

Synergy Pharma (NASDAQ: SGYP) reported Q1 EPS of ($0.51), $0.28 worse than the analyst estimate of ($0.23).

2016 is off to a strong and promising start for Synergy, highlighted by the U.S. Food and Drug Administration (FDA) acceptance of our first new drug application (NDA) for plecanatide in chronic idiopathic constipation (CIC), said Gary S. Jacob, Chairman and Chief Executive Officer of Synergy Pharmaceuticals. We continued to expand the utility and value of our uroguanylin-based platform technology while significantly strengthening our overall financial position. Moving forward, we believe we are well positioned to successfully execute on key... More